Dr. ZHONG is a Professor and the Director of Shanghai Center for Drug Metabolism and Pharmacokinetics Research at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Dr ZHONG’s research has centered on biotransformation and disposition of drugs, development of bioanalytical methods and technology, ADME studies of innovative drugs for regulatory filings and bioactivation of toxic components in herbal medicines. He has got 7 grants from the National Natural Science of China and had got His work has led to the discovery of a new variant CYP2C9*13 allele in Asian population and found the correlation of polymorphisms of CYP2C9 with metabolic clearance of lornoxicam and tolbutamide. His work led to the understanding of bioactivation mechanisms of natural products houttuyfonate, chlorogenic acid, and triptolide. 

During his 30 years of academic tenure, Dr. ZHONG co-authored over 340 SCI papers (cited >5200 times), and over 260 articles in Chinese journals (cited >3800 times), and co-edited three drug metabolism books and translated three books into Chinese. 

Dr. ZHONG has trained 48 PhD students and over 90 MS students, many of whom received various awards in international and national conferences and meetings. In addition, many of his former students are currently professor or associated professors in academic research organizations or hold DMPK leadership positions in pharmaceutical companies. 

His group has provided comprehensive ADME study services for more than 270 INDs, which accounted for about 30% of the total IND applications in China. Among them, 180 INDs have been approved for clinical trial in China and six INDs have been approved for clinical trial in the United States or Australia. In collaboration with hospitals, his group has conducted more than 100 studies of clinical DMPK. Of all the studies, 16 innovative drugs have been approved for marketing in China: Imrecoxib (2011), Icotinib (2011), Allisartan Isoproxil (2012), Morinidazole (2014), Apatinib (2014), Nemonoxacin (2016), Hemoporfin (2016), Pyrotinib (2018), Fruquintinib (2018), Carrimycin (2019), Flumatinib (2019), Remimazolam (2019), Almonertinib (2020), Fluzoparib (2020), Emitasvir (2020), Surufatinib (2020). In addition, his group has also conducted more than 400 bioequivalence studies.

Dr ZHONG has played a key role in development and establishment of drug metabolism and bioanalysis regulatory guidelines in China. He drafted “Guidance for Bioavailability and Bioequivalence Studies of Pharmaceutical Preparations” and “Guidance for Bioanalytical Methods Validation” for Chinese Pharmacopoeia (2015 Edition).

1.Zhu YT, Li L, Deng P, Chen XY, Zhong DF. Characterization of TPN729 metabolites in humans usingultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 117: 217–226

2.Zhang YF, Dai XJ, Yang Y, Chen XY, Wang T, Tang YB, Tsai CY, Chang LW, Chang YT, Zhong DF. Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers. Drug Design, Development and Therapy, 2016, 10: 357-370

3.Zhu YT, Li L, Zhang G, Wan H, Yang CY, Diao XX, Chen XY, Zhang LS, Zhong DF. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Journal of Chromatography B, 2016, 1033-1034: 117-127

4.Jiang JF, Pang XH, Li L, Dai XJ, Diao XX, Chen XY, Zhong DF, Wang YW, Chen YW. Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide. Drug Design, Development and Therapy, 2016, 10: 2181-2191

5.Yu MM, Gao ZW, Dai XJ, Gong H, Zhang LS, Chen XY, Zhong DF, Sy SKB. Population pharmacokibetic and covariate analysis of apatinib, an oral tyrosine kinase inhibitor, in healthy volunteers and patients with solid tumors. Clinical Pharmacokinetics, 2017, 56: 65-76

6.Zhang YF, Chen XY, Tang YB, Lu YM, Guo LX, Zhong DF. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study. Drug Design, Development and Therapy, 2017, 11: 2109-2119

7.Jiang JF, Chen XY, Zhong DF. Arylacetamide deacetylase is involved in vicagrel bioactivation in humans. Frontiers in Pharmacology, 2017, 8: 846(1-8) 

8.Zhou X, Zhang FR, Chen C, Guo ZT, Liu J, YuJ H, Xu Y, Zhong DF, Jiang HL. Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. Xenobiotica, 2017, 47: 267-275

9.Xu Y, Zhang YF, Chen XY, Zhong DF. CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats. Acta Pharmacologica Sinica, 2018, 39: 1386-1392

10.Zhang D, Yang CY, Chen XY, Li XL, Zhong DF. A bridging immunogenicity assay for monoclonal antibody: case study with SHR-1222. Bioanalysis, 2018, 10: 1115-1117

11.Liu XY, Zhang YF, Chen Q, Zhan Y, Wang QR, Hu CY, Yu C, Guo ZT, Chen XY, Zhong DF. Pharmacokinetic drug interactions of apatinib with rifampin and itraconazole. Journal of Clinical Pharmacology, 2018, 58: 347-356

12.Liu C, Lu YM, Sun HB, Yang J, Liu YQ, Lai XJ, Gong YC, Liu XF, Li YG, Zhang YF, Chen XY, Zhong DF. Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149: 394-402

13.Jiang JF, Chen XY, Zhong DF. Predominant contribution of carboxylesterase 1 and 2 in hydrolysis of anordrin in human. Xenobiotica, 2018, 48: 533-540

14.Zhu YQ, Romero EL, Ren XD, Sanca AJ, Du CK, Liu C, Karim ZA, Alshbool FZ, Khasawneh FT, Zhou J, Zhong DF, Geng B. Clopidogrel as a donor probe and thioenol derivatives as flexible promoieties for enabling H2S biomedicine. Nature Communications, 2018, 9: 3952

15.Meng J, Liu XY, Ma S, Zhang H, Yu SD, Zhang YF, Chen MX, Zhu XY, Liu Y, Yi L, Ding XL, Chen XY, Miao LY, Zhong DF. Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein. Acta Pharmacologica Sinica, 2019, 40: 980-988

16.Petain A, Zhong DF, Chen XY, Zhang L, Shao ZM, Jiang ZF, Zorza G, Perre P. Effect of ethnicity on vinorelbin pharmacokinetics: a population pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology, 2019, 84: 373-382

17.Li XL, Sun JC, Guo ZT, Zhong DF, Chen XY. Carboxylase 2 and intestine transporters contribute to the low bioavailability of allisartan, a prodrug of Exp3174 for hypertension treatment in humans. Drug Metabolism and Disposition, 2019, 47: 843-853

18.Liu C, Zhang YF, Chen WL, Lu YM, Li W, Liu YQ, Lai XJ, Gong YC, Liu XF, Li YG, Chen XY, Li XN, Sun HB, Yang J, Zhong DF. Pharmacokinetics and pharmacokinetic/ pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. European Journal of Pharmaceutical Sciences, 2019, 127: 151-160

19.Pan LL, Guo S, Chen XY, Jiang XR, Shen JS, Diao XX, Wang Z, Zhong DF. Characterization of TPN171 metabolism in humans via ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172: 302-310

20.Gao YX, Zhang D, Yang CY, Duan XT, Li XL, Zhong DF. Two validated liquid chromatography-mass spectrometry methods with different pretreatment for the quantification of an anti-CD47 monoclonal antibody in rat and cynomolgus monkey serum comparing with an electrochemiluminescence method. Journal of Pharmaceutical and Biomedical Analysis, 2019, 175: 112792

21.Liu XY, Wei Li, Zhang YF, Yong Jiang, Qianyu Zhao, Zhong DF. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2019, 176: 112735

22.Chen ZD, Gao YX, Zhong DF. Technologies to improve the sensitivity of existing chromatographic methods used for bioanalytical studies. Biomedical Chromatography, 2020, 34: e4798

23.Zhang YF, Zhu XX*, Zhan Y, Li XJ, Liu C, YT Zhu, Zhang H, Wei HJ, Xia Y, Sun HB, Li YQ, Lai XJ, Gong YC, Liu XF, Li YG, Ding YH, Zhong DF. Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on vicagrel, a novel thienopyridine P2Y12. British Journal of Clinical Pharmacology, 2020, 86: 1860-1874

24.Shi YK, Zhang S, Hu X, Feng J, Ma Z, Zhou J, Yang N, Wu L, Liao W, Zhong DF, Han X, Wang Z, Zhang X, Qin S, Ying K, Feng J, Fang J, Liu L, Jiang Y. Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with Advanced NSCLC with EGFR T790M mutation. Journal of Thoracic Oncology, 2020, 15: 1015-1026

25.Zhu YT, Teng Z, Zhang YF, Li W, Guo LX, Qu XJ, Wang QR, Mao SY, Chen XY, Zhong DF. Effects of apatinib on the pharmacokinetics of nifedipine and warfarin in patients with advanced solid tumors. Drug Design, Development and Therapy, 2020, 14: 1963-1970  

26.Jiang JF, Li L, Lu YM, Chen YH, Chen XY, Zhong DF. Direct quantification of anorethidrani disuccinate and determination of sterol metabolite by chemical derivatization combined with LC-MS/MS: application to a Phase I pharmacokinetic study in humans. Journal of Chromatography B, 2020, 1157: 122290

27.Liu XY, Feng D, Zheng MY, Zhong DF. Characterization of some covalent tyrosine kinase inhibitors covalent binding to human plasma protein. Drug Metabolism and Pharmacokinetics, 2020, 35: 456-465

28.Liu XY, Guo ZT, Zhang YF, Zhou JL, Jiang Y, Zhao QY, Diao XX, Zhong DF. Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacologica Sinica, 2020, 41: 1366-1376

29.Chen ZD, Li L, Zhan Y, Zhang YF, Liu HY, Zou JJ, Zhong DF. Characterization and quantitative determination of henagliflozin metabolites in humans. Journal of Pharmaceutical and Biomedical Analysis, 2021, 192: 113632